1. Home
  2. GLMD vs SNOA Comparison

GLMD vs SNOA Comparison

Compare GLMD & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galmed Pharmaceuticals Ltd.

GLMD

Galmed Pharmaceuticals Ltd.

HOLD

Current Price

$1.14

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$3.38

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLMD
SNOA
Founded
2000
1999
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
6.5M
IPO Year
2014
2007

Fundamental Metrics

Financial Performance
Metric
GLMD
SNOA
Price
$1.14
$3.38
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.3M
17.4K
Earning Date
11-26-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,937,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.02
52 Week Low
$0.74
$1.75
52 Week High
$3.61
$6.92

Technical Indicators

Market Signals
Indicator
GLMD
SNOA
Relative Strength Index (RSI) 53.66 48.26
Support Level $0.81 $3.14
Resistance Level $0.99 $3.46
Average True Range (ATR) 0.13 0.23
MACD 0.03 0.01
Stochastic Oscillator 49.70 60.78

Price Performance

Historical Comparison
GLMD
SNOA

About GLMD Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: